PLYX — Polaryx Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2075320 ·
Last close
$1.60
Market Cap
$75.75M
52W High
$48.91
52W Low
$1.58
ADV30
25,872
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -3,328,000 | -3,328,000 | 8,610,000 | 8,440,000 | 999,000 |
| Jun 2026 | 0 | — | -1,380,000 | -1,380,000 | 11,812,000 | 11,542,000 | 873,000 |
| Mar 2026 | 0 | — | -1,958,000 | -2,544,000 | 3,502,000 | 3,080,000 | 1,014,000 |
| Dec 2025 | 0 | — | -911,000 | -1,495,000 | 5,170,000 | 5,143,000 | 605,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,809,000
Investing CF
—
Financing CF
$14,047,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-103,559,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-5,223,000
Pretax Income TTM
$-6,849,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,821,000 | -8,985,000 | 5,170,000 | 605,000 | 4,565,000 | -3,944,000 |
| Dec 2024 | 0 | -4,352,000 | -30,356,000 | 5,001,000 | 289,000 | 4,712,000 | -2,573,000 |
| Dec 2023 | 0 | -3,781,000 | -3,779,000 | 2,315,000 | 1,038,000 | 1,277,000 | -173,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$11,812,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MAIA | MAIA Biotechnology, Inc. | $77.19M | $1.25 | — |
| RACC | Research Alliance Corp III | $78.68M | $10.12 | — |
| ZYBT | Zhengye Biotechnology Holding Ltd | $72.03M | $1.52 | — |
| COYA | Coya Therapeutics, Inc. | $70.84M | $3.02 | — |
| RLYB | Rallybio Corp | $82.32M | $15.29 | — |
News headlines (Yahoo Finance, 1h cache)
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
2026-11-09 13:30 · Yahoo
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
2026-09-01 12:30 · Yahoo
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
2026-08-25 12:30 · Yahoo
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
2026-04-23 12:30 · Yahoo
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
2026-05-28 12:30 · Yahoo
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
2026-04-15 13:15 · Yahoo
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
2026-05-14 13:15 · Yahoo
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
2026-04-21 12:30 · Yahoo
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
2026-04-01 12:30 · Yahoo
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
2026-03-17 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.